Resveratrol as a sensitizer to apoptosis-inducing stimuli

Resveratrol in Health and Disease

Volumn , Issue , 2005, Pages 399-422

  Jazirehi, Ali R ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954138804     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420026474     Document Type: Chapter

References (79)

1. Patel NH and Rothenberg ML, Multidrug resistance in cancer chemotherapy, Invest New Drugs 12, 1-13, 1994.
2. Klaus SJ, Sidorenko SP, and Clark EA, CD45 ligation induces programmed cell death in T and B lymphocytes, J Immunol 156, 2743-2753, 1996.
3. Thompson I, Feigl P, and Coltman C, Chemoprevention of prostate cancer with finasteride, Important Adv Oncol 57-76, 1995.
4. Shresta S, Pham CT, Thomas DA, Graubert TA, and Ley TJ, How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 10, 581-587, 1998.
5. Ashkenazi A and Dixit VM, Death receptors: signaling and modulation, Science 281, 1305-1308, 1998.
6. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, and Peter ME, Two CD95 (APO-1/Fas) signaling pathways, EMBO J 17, 1675-1687, 1998.
7. Ng CP and Bonavida B, A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance, Adv Cancer Res 85, 145-174, 2002.
8. Ferreria CG, Epping M, Kruyt FAE, and Giaccone G, Apoptosis: target of cancer therapy, Clin Cancer Res 8, 2024-2034, 2002.
9. Sandor V, Wilson W, Fojo T, and Bates SE, The role of MDR-1 in refractory lymphoma, Leuk Lymphoma 28, 23-31, 1997.
10. Filipits M, Jaeger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, and Pirker, R, Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas, Clin Cancer Res 6, 3417-3423, 2000.
11. Reed JC, Bcl-2 family proteins: regulators of chemoresistance in cancer, Toxicol Lett 82, 155-158, 1995.
12. Minn AJ, Rudin CM, Boise LH, and Thompson CB, Expression of Bcl-xL can confer a multi-drug resistance phenotype, Blood 86, 1903-1910, 1995.
13. Jazirehi AR, Ng C-P, Gan X-H, Schiller G, and Bonavida BB, Adriamycin sensitized the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/TRAIL mediated apoptosis, Clin Cancer Res 7, 3874-3883, 2001.
14. Tan B, Piwnica-Worms D, and Ratner L, Multidrug resistance transporters and modulation, Curr Opin Oncol 12, 450-458, 2000.
15. Kaufmann SH and Earnshaw WC, Induction of apoptosis by cancer chemotherapy, Exp Cell Res 256, 42-49, 2000.
16. Jazirehi AR and Bonavida B, Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin’s lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis, Mol Cancer Ther 3, 71-84, 2004.
17. Park EJ and Pezzuto JM, Botanicals in cancer chemoprevention, Cancer Metastasis Rev 21, 231-255, 2002.
18. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, and Bonavida B, Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities, Curr Med Chem Anti-Cancer Agents 3, 77-93, 2003.
19. Nonomura S, Kanagawa H, and Makimoto A, Chemical constituents of polygonaceous plants: I. Studies on the components of Ko-jo-kon (Polygonum cuspidatum SIEB et ZUCC), Yakugaku Zasshi 83, 983-988, 1963.
20. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, and Pezzuto JM, Cancer chemo-preventive activity of resveratrol, a natural product derived from grapes, Science 275, 218-220, 1997.
21. Pervaiz S, Resveratrol: from grapevines to mammalian biology, FASEB J 17, 1975, 2003.
22. Bianchini F and Vainioh H, Wine and resveratrol: mechanisms of cancer prevention? Eur J Cancer Prev 12, 417-425, 2003.
23. Wu SL, Sun ZJ, Yu L, Meng KW, Qin XL, and Pan CE, Effect of resveratrol and in combination with 5-FU on murine liver cancer, World J Gastroenterol 10, 3048-3052, 2004.
24. Chen Y, Tseng SH, Lai HS, and Chen WJ, Cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice, Surgery 136, 57-66, 2004.
25. Fuggetta MP, D’Atri S, Lanzilli G, Tricarico M, Cannavo E, Zambruno G, Falchetti R, and Ravagnan G, In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide, Melanoma Res 14, 189-196, 2004.
26. Niles RM, McFarland M, Weimer MB, Redkar A, Fu YM, and Meadows GG, Resveratrol is a potent inducer of apoptosis in human melanoma cells, Cancer Lett 190, 157-163, 2003.
27. Laux MT, Aregullin M, Berry JP, Flanders JA, and Rodriguez E, Identification of a p53-dependent pathway in the induction of apoptosis of human breast cancer cells by the natural product, resveratrol, J Alternative Complementary Med 10, 235-239, 2004.
28. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, and Ghidoni R, Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling, FASEB J 17, 2339-2341, 2003.
29. Ding XZ and Adrian TE, Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells, Pancreas 25, e71-76, 2002.
30. Kuo PL, Chiang LC, and Lin CC, Resveratrol-induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells, Life Sci 72, 23-34, 2002.
31. Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC, Mohammad R, Mossalayi DM, and Kolb JP, Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia, Br J Haematol 117, 842-851, 2002.
32. Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, and Reddy GP, Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA synthesis, Cancer Res 62, 2488-2492, 2002.
33. Kim YA, Rhee SH, Park KY, and Choi YH, Antiproliferative effect of resveratrol in human prostate carcinoma cells, J Med Food 6, 273-280, 2003.
34. Wang Q, Li H, Wang XW, Wu DC, Chen XY, and Liu J, Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells, Neurosci Lett 35, 83-86, 2003.
35. Narayanan BA, Narayanan NK, Re GG, and Nixon DW, Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets, Int J Cancer 104, 204-212, 2003.
36. Hung LM, Chen JK, Lee RS, Liang HC, and Su MJ, Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart, Free Radical Biol Med 30, 877-883, 2001.
37. Ito T, Akao Y, Tanaka T, Iinuma M, and Nozawa Y, Vaticanol C, A novel resveratrol tetramer, inhibits cell growth through induction of apoptosis in colon cancer cell lines, Biol Pharm Bull 25, 147-148, 2002.
38. Wolter F, Clausnitzer A, Akoglu B, and Stein J, Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines, J Nutr 132, 298-302, 2002.
39. Alas S and Bonavida B, Rituximab inactivates STAT3 activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs, Cancer Res 61, 5137-5144, 2001.
40. Park JH, Min HY, Kim SS, Lee JY, Lee SK, and Lee YS, Styrylquinazolines:a new class of inhibitors on prostaglandin E2 production in lipopolysaccharideactivated macrophage cells, Arch Pharm (Weinheim) 337, 20-24, 2004.
41. Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP, and Gescher AJ, Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,40-tetramethoxystilbene, Br J Cancer 90, 736-744, 2004.
42. Kerem Z, Regev-Shoshani G, Flaishman MA, and Sivan L, Resveratrol and two monomethylated stilbenes from Israeli Rumex bucephalophorus and their antioxidant potential, J Nat Prod 66, 1270-1272, 2003.
43. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, and Tolomeo M, Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents, J Med Chem 46, 3546-3554, 2003.
44. Lee SK, Nam KA, Hoe YH, Min HY, Kim EY, Ko H, Song S, Lee T, and Kim S, Synthesis and evaluation of cytotoxicity of stilbene analogues, Arch Pharm Res 26, 253-257, 2003.
45. Cai YJ, Fang JG, Ma LP, Yang L, and Liu ZL, Inhibition of free radicalinduced peroxidation of rat liver microsomes by resveratrol and its analogues, Biochim Biophys Acta 1637, 31-38, 2003.
46. Gusman J, Malonne H, and Atassi G, A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol, Carcinogenesis 22, 1111-1117, 2001.
47. Chun YJ, Kim MY, and Guengerich FP, Resveratrol is a selective human cytochrome p450 1A1 inhibitor, Biochem Biophys Res Commun 262, 20-24, 1999.
48. Ciolino HP and Yeh GC, Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol, Mol Pharmacol 56, 760-767, 1999.
49. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM, and Castanas E, Potent inhibitory action of red wine polyphenols on human breast cancer cells, J Cell Biochem 78, 429-441, 2000.
50. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, and Dannenberg AJ, Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells, J Biol Chem 273, 21875-21882, 1998.
51. Banerjee S, Bueso-Ramos C, and Aggarwal BB, Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9, Cancer Res 62, 4945-4954, 2002.
52. Holmes-McNary M, and Baldwin AS Jr, Chemopreventive properties of transresveratrol are associated with inhibition of activation of the IkappaB kinase, Cancer Res 60, 3477-3483, 2000.
53. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, and Schwall RH, Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest 104, 155-162, 1999.
54. Kelley SK and Ashkenazi A, Targeting death receptors in cancer with Apo2L/TRAIL, Curr Opin Pharmacol 4, 333-339, 2004.
55. Fulda S and Debatin KM, Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol, Cancer Res 64, 337-346, 2004.
56. Fulda S and Debatin KM, Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol, Oncogene 23, 6702-6711, 2004.
57. Roy N, Deveraux QL, Takahashi R, Salvesen GS, and Reed JC, The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases, EMBO J 16, 6914-6925, 1997.
58. Deveraux QL, Roy N, Stennicke HR, Arsdale TV, Zhou Q, Srinivasula SM et al, IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases, EMBO J 17, 2215-2223, 1998.
59. Kubota T, Uemura Y, Kobayashi M, and Taguchi H, Combined effects of resveratrol and paclitaxel on lung cancer cells, Anticancer Res 23, 4039-4046, 2003.
60. Nakagawa H, Kiyozuka Y, Uemura Y, Shikata N, Hioki K, and Tsubura A, Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator, J Cancer Res Clin Oncol 127, 258-264, 2001.
61. Ibrado AM, Liu L, and Bhalla K, Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of acute myeloid leukemia HL-60 cells, Cancer Res 57, 1109-1116, 1997.
62. Sevilla L, Zaldumbide A, Pognonec P, and Boulukos KE, Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NF-nB, STAT and AP-1 transcription factor families, Histol Histopathol 16, 595-601, 2001.
63. El-Mowafy AM and White RE, Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects, FEBS Lett 451, 63-67, 1999.
64. MacKeigan JP, Collins TS, and Ting JP-Y, MEK inhibition enhances paclitaxel-induced tumor apoptosis, J Biol Chem 275, 38953-38956, 2000.
65. Dai Y, Yu C, Sing V, Tang L, Wang Z, Molinstry R et al, Pharmacological inhibitors of the mitogen activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells, Cancer Res 61, 5106-5115, 2001.
66. Zhang B, Gojo I, and Fenton RG, Myeloid cell factor-1 is a critical survival factor for multiple myeloma, Blood 99, 1885-1893, 2002.
67. Pagnano KB, Silva MD, Vassallo J, Aranha FJ, and Saad ST, Apoptosis regulating proteins and prognosis in diffuse large B cell non-Hodgkin’s lymphomas, Acta Haematol 107, 29-34, 2002.
68. Rassidakis GZ, Lai R, McDonnell TJ, Cabanilla F, Sarris AH, and Mederios LJ, Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors, Am J Pathol 160, 2309-2310, 2002.
69. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al, Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential protein of human myeloma cells, Blood 100, 194-199, 2002.
70. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D et al, The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction, Blood 99, 1038-1043, 2002.
71. Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW et al, Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism, Biochem Pharmacol 62, 1469-1480, 2001.
72. Shan D, Ledbetter JA, and Press OW, Apoptosis of malignant human B cells by ligation of CD20 with mAbs, Blood 91, 1644-1652, 1998.
73. Huang HM, Huang CJ, and Yen JJ, Mcl-1 is a common target of stem cell factor and IL-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/AKT pathways, Blood 96, 1764-1771, 2000.
74. Schubert KM and Duroino V, Distinct roles of extracellular-signal regulated protein kinase (ERK) mitogen activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis, Biochem J 356, 473-480, 2001.
75. Rowinsky ER and Donehower RC, Antimicrotubule agents, in Cancer Chemotherapy and Biotherapy, 2nd ed, Lippincott, Williams and Wilkins, Philadelphia, 1996, pp. 263-292.
76. Gewirtz DA, A critical evaluation of the mechanism of action proposed for the antitumor effects of anthracycline antibiotics adriamycin and daunorubicin, Biochem Pharmacol 57, 772-741, 1999.
77. Trimmer EE and Essigmann JM, Cisplatin, Essays Biochem 34, 191-211, 1999.
78. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, and Ducharme MP, Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model, J Pharmacol Exp Ther 302, 369-373, 2002.
79. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J, and Merillon JM, Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration, Life Sci 72, 2219-2233, 2003.